Tirzepatide for Psoriatic Arthritis

Recruiting at 55 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Eli Lilly and Company

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for people with active Psoriatic Arthritis (PsA) who are also overweight or obese and have at least one weight-related health issue. Participants should already be receiving ixekizumab therapy as part of their standard care.

Inclusion Criteria

I can start tirzepatide within 30 days of deciding to treat.

I have been diagnosed with active psoriatic arthritis by a specialist.

I have been treated with ixekizumab for about 3 months before starting tirzepatide.

Exclusion Criteria

I have had pancreatitis before.

I have had severe stomach or digestion problems like gastroparesis or GERD.

Are currently enrolled in any other clinical study

Treatment Details

Interventions

• Tirzepatide (Other)

Trial Overview The study tests the effectiveness of adding a medication called tirzepatide to existing ixekizumab treatment in patients with PsA and obesity over a period of up to 12 months, observing how well it works in regular clinical settings.

Participant Groups

Group I: Tirzepatide Experimental Treatment 1 Intervention

Participants will continue on ixekizumab and take tirzepatide administered subcutaneously (SC) as per label.

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University